A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib
Status:
Not yet recruiting
Trial end date:
2023-08-07
Target enrollment:
Participant gender:
Summary
A Phase 1, Open-label, Multiple-dose, One-sequence Crossover Study to Investigate the Effect
of Repeated Oral Doses of a Strong CYP2C8 Inhibitor on the Steady-state Pharmacokinetics of
Adagrasib in Healthy Adult Subjects